696 related articles for article (PubMed ID: 28994164)
1. Utilization of increased risk for transmission of infectious disease donor organs in solid organ transplantation: Retrospective analysis of disease transmission and safety.
Irwin L; Kotton CN; Elias N; Palafox J; Basler D; Shao SH; Lester W; Zhang X; Kimball B; Trencher C; Fishman JA
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28994164
[TBL] [Abstract][Full Text] [Related]
2. Organ utilization from increased infectious risk donors: An observational study.
L'Huillier AG; Humar A; Payne C; Kumar D
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28981193
[TBL] [Abstract][Full Text] [Related]
3. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020.
Jones JM; Kracalik I; Levi ME; Bowman JS; Berger JJ; Bixler D; Buchacz K; Moorman A; Brooks JT; Basavaraju SV
MMWR Recomm Rep; 2020 Jun; 69(4):1-16. PubMed ID: 32584804
[TBL] [Abstract][Full Text] [Related]
4. Organ transplantation from "increased infectious risk donors": the experience of the Nord Italia Transplant program - A retrospective study.
Grossi PA; Dalla Gasperina D; Lombardi D; Ricci A; Piccolo G; Nanni Costa A
Transpl Int; 2018 Feb; 31(2):212-219. PubMed ID: 29057524
[TBL] [Abstract][Full Text] [Related]
5. A model to estimate the probability of human immunodeficiency virus and hepatitis C infection despite negative nucleic acid testing among increased-risk organ donors.
Annambhotla PD; Gurbaxani BM; Kuehnert MJ; Basavaraju SV
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28178393
[TBL] [Abstract][Full Text] [Related]
6. Donor-Derived Infections: Monitoring of Posttransplant Infections and Safety Lessons From the Opioid Epidemic.
Fishman JA; Irwin L
Exp Clin Transplant; 2022 Aug; 20(Suppl 4):20-23. PubMed ID: 36018015
[TBL] [Abstract][Full Text] [Related]
7. Screening recipients of increased-risk donor organs: a survey of transplant infectious diseases physician practices.
Theodoropoulos N; Ladner DP; Ison MG
Transpl Infect Dis; 2013 Oct; 15(5):545-9. PubMed ID: 23901896
[TBL] [Abstract][Full Text] [Related]
8. Excerpt from PHS guideline for reducing HIV, HBV and HCV transmission through organ transplantation.
Seem DL; Lee I; Umscheid CA; Kuehnert MJ
Am J Transplant; 2013 Aug; 13(8):1953-62. PubMed ID: 23890284
[TBL] [Abstract][Full Text] [Related]
9. Deceased organ donor screening for HIV, hepatitis B, and hepatitis C viruses: a survey of organ procurement organization practices.
Theodoropoulos N; Jaramillo A; Ladner DP; Ison MG
Am J Transplant; 2013 Aug; 13(8):2186-90. PubMed ID: 23711196
[TBL] [Abstract][Full Text] [Related]
10. Deceased organ donor screening for human immunodeficiency virus, hepatitis B virus and hepatitis C virus: Discordant serology and nucleic acid testing results.
Theodoropoulos N; Nowicki MJ; Chinchilla-Reyes C; Dionne S; Jaramillo A; Mone T; Hasz R; Jendrisak MD; Ladner DP; Ison MG
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29178242
[TBL] [Abstract][Full Text] [Related]
11. Utilization of deceased organ donors based on HIV, hepatitis B virus, and hepatitis C virus screening test results.
Theodoropoulos N; Kroll-Desrosiers A; Ison MG
Transpl Infect Dis; 2020 Aug; 22(4):e13275. PubMed ID: 32144838
[TBL] [Abstract][Full Text] [Related]
12. Deceased Organ Donors and PHS Risk Identification: Impact on Organ Usage and Outcomes.
Pruett TL; Clark MA; Taranto SE
Transplantation; 2017 Jul; 101(7):1670-1678. PubMed ID: 28252560
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B and C serologic profiles of Canadian organ donors and recipients: retrospective 10-year review at a single center.
Burton CE; Doucette KE; Mabilangan CA; Plitt SS; Lee BE; Preiksaitis JK
Transpl Infect Dis; 2016 Aug; 18(4):520-8. PubMed ID: 27226204
[TBL] [Abstract][Full Text] [Related]
14. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
[TBL] [Abstract][Full Text] [Related]
15. Impact of repeat testing of living kidney donors within 14 days of the transplant procedure: a multicenter retrospective survey.
Echenique IA; Cohen D; Rudow DL; Ison MG
Transpl Infect Dis; 2014 Jun; 16(3):403-11. PubMed ID: 24796964
[TBL] [Abstract][Full Text] [Related]
16. Screening recipients of increased risk donor organs: A multicenter retrospective study.
Ison MG; Rana MM; Brizendine KD; Chimienti S; Le J; Kfoury R; Mohazabnia P; Theodoropoulos N
Transpl Infect Dis; 2018 Jun; 20(3):e12862. PubMed ID: 29512233
[TBL] [Abstract][Full Text] [Related]
17. Impact of US Public Health Service increased risk deceased donor designation on organ utilization.
Sapiano MRP; Jones JM; Bowman J; Levi ME; Basavaraju SV
Am J Transplant; 2019 Sep; 19(9):2560-2569. PubMed ID: 30959569
[TBL] [Abstract][Full Text] [Related]
18. Utilizing increased risk for disease transmission (IRD) kidneys for pediatric renal transplant recipients.
Hwang CS; Gattineni J; MacConmara M
Pediatr Nephrol; 2019 Oct; 34(10):1743-1751. PubMed ID: 31243535
[TBL] [Abstract][Full Text] [Related]
19. Deceased tissue donor serology and molecular testing for HIV, hepatitis B and hepatitis C viruses: a lack of cadaveric validated tests.
Victer TN; Dos Santos CS; Báo SN; Sampaio TL
Cell Tissue Bank; 2016 Dec; 17(4):543-553. PubMed ID: 27329292
[TBL] [Abstract][Full Text] [Related]
20. Early experience with the use of hepatitis C antibody-positive, nucleic acid testing-negative donors in lung transplantation.
Watson J; Mulvihill MS; Cox ML; Rich L; Wolfe CR; Gray A; Hartwig MG
Clin Transplant; 2019 Mar; 33(3):e13476. PubMed ID: 30609162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
